By targeting misfolded transthyretin (TTR), CRISPR/Cas9 has been used in the treatment of transthyretin (ATTR) amyloidosis by targeting misfolded transthyretin (TTR), and the safety and pharmacodynamic effects of NTLA-2001 have been evaluated in an ongoing clinical study (170). This evidence concerns the gene TTR and amyloidosis.